• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

CCT020312 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754683

CCT020312 is a selective activator of EIF2AK3/PERK and elicits EIF2A phosphorylation in cells. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
CCT020312, Inhibitor
Full Product Name
CCT020312
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
650.4
Solubility
DMSO: 125mg/mL (192.19mM) Need ultrasonic
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C31H30Br2N4O2
SMILES
O=C1NC2=C(C(C3=CC=CC=C3)=C1C4=NN(C(C4)C5=CC=C(C=C5)Br)C(CCN(CC)CC)=O)C=C(C=C2)Br
CAS Number
324759-76-4
Target & IC50
EIF2AK3/PERK
In Vitro
P301S transgenic mice treated with CCT020312 (2mg/kg; i.p.; once daily for 6 weeks) perform significantly better in Morris water maze. treatment of 15-week-old wild-type mice with the PERK activator CCT020312 (1-5mg/kg; i.p.; once daily for 3 days) leads to increased levels of phosphorylated PERK and NRF2 in brain homogenates [2].

Structure of CCT020312, inhibitor

CCT020312 Inhibitor – Cat# MBS5754683

Product References and Citations for CCT020312, inhibitor

Stockwell SR, et al.Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568.
Stockwell SR, et al.Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 2012;7(1):e28568.
Bruch J, et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med. 2017 Mar;9(3):371-384.
Bruch J, et al. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med. 2017 Mar;9(3):371-384.

Other Notes

Small volumes of CCT020312, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for CCT020312 purchase

MBS5754683 is an inhibitor targeting CCT020312.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000